Your browser doesn't support javascript.
loading
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.
Velaparthi, Upender; Wittman, Mark; Liu, Peiying; Carboni, Joan M; Lee, Francis Y; Attar, Ricardo; Balimane, Praveen; Clarke, Wendy; Sinz, Michael W; Hurlburt, Warren; Patel, Karishma; Discenza, Lorell; Kim, Sean; Gottardis, Marco; Greer, Ann; Li, Aixin; Saulnier, Mark; Yang, Zheng; Zimmermann, Kurt; Trainor, George; Vyas, Dolatrai.
Affiliation
  • Velaparthi U; Discovery Chemistry, Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Co., Wallingford, Connecticut 06492, USA. upender.velaparthi@bms.com
J Med Chem ; 51(19): 5897-900, 2008 Oct 09.
Article in En | MEDLINE | ID: mdl-18763755

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridones / Benzimidazoles / Receptor, IGF Type 1 / Protein Kinase Inhibitors / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2008 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridones / Benzimidazoles / Receptor, IGF Type 1 / Protein Kinase Inhibitors / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2008 Type: Article Affiliation country: United States